Evidence map›Paper›PMID 42595754›Full record

ReviewNature reviews. Disease primers2026

Methicillin-resistant Staphylococcus aureus.

Joshua B Parsons, Annette C Westgeest, Brian P Conlon, Stephan Harbarth, Benjamin P Howden, Yang Soo Kim, Heather A King, Merel M C Lambregts, Loren G Miller, Robin Patel and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joshua B Parsons *Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Annette C Westgeest *Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Brian P ConlonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Stephan HarbarthInfection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Benjamin P HowdenMicrobiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Yang Soo KimDivision of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
Heather A KingDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Merel M C LambregtsLeiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-3637-9115
Loren G MillerDivision of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center and Lundquist Institute at Harbor-UCLA, Torrance, CA, USA.
Robin PatelDivision of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Minggui WangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-7682-5859
Vance G FowlerDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA. vance.fowler@duke.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of antimicrobial-resistant infection worldwide. The spectrum of diseases caused by MRSA range from uncomplicated skin and soft-tissue infections to life-threatening invasive infections such as bacteraemia, pneumonia, osteomyelitis and endocarditis. MRSA commonly colonizes the skin and mucosal surfaces as an asymptomatic commensal but can transition to an invasive pathogen when host barriers are disrupted or immune defences are compromised. The shift from commensal to pathogen is facilitated by a broad repertoire of virulence factors that promote adhesion, immune evasion, tissue invasion and persistence within host tissues. Despite the development of several new antibiotics with activity against MRSA, clinical outcomes during invasive infections are poor, with many patients experiencing persistent or recurrent infection. Strategies to prevent MRSA infection include infection control measures, screening and targeted decolonization approaches; however, the effectiveness of these interventions varies and often depends on local MRSA prevalence and epidemiological context. Understanding the epidemiology, pathogenesis and clinical management of MRSA remains essential to guide effective prevention and treatment strategies.

Indexed as

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnti-Bacterial AgentsHumansAnti-Bacterial Agents

Identifiers

PMID42595754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.